These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 20135628)

  • 1. Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry.
    Wimalasena K
    Med Res Rev; 2011 Jul; 31(4):483-519. PubMed ID: 20135628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter.
    Erickson JD; Schafer MK; Bonner TI; Eiden LE; Weihe E
    Proc Natl Acad Sci U S A; 1996 May; 93(10):5166-71. PubMed ID: 8643547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Individual residues contribute to multiple differences in ligand recognition between vesicular monoamine transporters 1 and 2.
    Finn JP; Edwards RH
    J Biol Chem; 1997 Jun; 272(26):16301-7. PubMed ID: 9195934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic variants in the vesicular monoamine transporter 1 (VMAT1/SLC18A1) and neuropsychiatric disorders.
    Lohoff FW
    Methods Mol Biol; 2010; 637():165-80. PubMed ID: 20419435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vesicular amine transporter expression and isoform selection in developing brain, peripheral nervous system and gut.
    Schütz B; Schäfer MK; Eiden LE; Weihe E
    Brain Res Dev Brain Res; 1998 Mar; 106(1-2):181-204. PubMed ID: 9555003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Localization of vesicular monoamine transporter isoforms (VMAT1 and VMAT2) to endocrine cells and neurons in rat.
    Weihe E; Schäfer MK; Erickson JD; Eiden LE
    J Mol Neurosci; 1994; 5(3):149-64. PubMed ID: 7654518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A fluorescent-based assay for live cell, spatially resolved assessment of vesicular monoamine transporter 2-mediated neurotransmitter transport.
    Bernstein AI; Stout KA; Miller GW
    J Neurosci Methods; 2012 Aug; 209(2):357-66. PubMed ID: 22698664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vesicular monoamine transporter 2: role as a novel target for drug development.
    Zheng G; Dwoskin LP; Crooks PA
    AAPS J; 2006 Nov; 8(4):E682-92. PubMed ID: 17233532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of the two isoforms of the vesicular monoamine transporter (VMAT1 and VMAT2) in the endocrine pancreas and pancreatic endocrine tumors.
    Anlauf M; Eissele R; Schäfer MK; Eiden LE; Arnold R; Pauser U; Klöppel G; Weihe E
    J Histochem Cytochem; 2003 Aug; 51(8):1027-40. PubMed ID: 12871984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ontogeny of vesicular monoamine transporter mRNAs VMAT1 and VMAT2. I. The developing rat central nervous system.
    Hansson SR; Hoffman BJ; Mezey E
    Brain Res Dev Brain Res; 1998 Sep; 110(1):135-58. PubMed ID: 9733951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Involvement of vesicular monoamine transporter in attention deficit hyperactivity disorder].
    Lorenzo-Sanz G; Sánchez-Herranz A
    Rev Neurol; 2011 Mar; 52 Suppl 1():S103-8. PubMed ID: 21365590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemistry and molecular biology of the vesicular monoamine transporter from chromaffin granules.
    Henry JP; Botton D; Sagne C; Isambert MF; Desnos C; Blanchard V; Raisman-Vozari R; Krejci E; Massoulie J; Gasnier B
    J Exp Biol; 1994 Nov; 196():251-62. PubMed ID: 7823026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group.
    Temple W; Mendelsohn L; Kim GE; Nekritz E; Gustafson WC; Lin L; Giacomini K; Naranjo A; Van Ryn C; Yanik GA; Kreissman SG; Hogarty M; Matthay KK; DuBois SG
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):474-481. PubMed ID: 26338179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transport and inhibition mechanisms of human VMAT2.
    Wu D; Chen Q; Yu Z; Huang B; Zhao J; Wang Y; Su J; Zhou F; Yan R; Li N; Zhao Y; Jiang D
    Nature; 2024 Feb; 626(7998):427-434. PubMed ID: 38081299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential expression of vesicular monoamine transporter (VMAT) 1 and 2 in gastrointestinal endocrine tumours.
    Jakobsen AM; Andersson P; Saglik G; Andersson E; Kölby L; Erickson JD; Forssell-Aronsson E; Wängberg B; Ahlman H; Nilsson O
    J Pathol; 2001 Nov; 195(4):463-72. PubMed ID: 11745679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential expression of two vesicular monoamine transporters.
    Peter D; Liu Y; Sternini C; de Giorgio R; Brecha N; Edwards RH
    J Neurosci; 1995 Sep; 15(9):6179-88. PubMed ID: 7666200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of neurotransmitter transport and drug inhibition in human VMAT2.
    Pidathala S; Liao S; Dai Y; Li X; Long C; Chang CL; Zhang Z; Lee CH
    Nature; 2023 Nov; 623(7989):1086-1092. PubMed ID: 37914936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural mechanisms for VMAT2 inhibition by tetrabenazine.
    Dalton MP; Cheng MH; Bahar I; Coleman JA
    Elife; 2024 Mar; 12():. PubMed ID: 38517752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VMAT2 inhibitors for the treatment of hyperkinetic movement disorders.
    Koch J; Shi WX; Dashtipour K
    Pharmacol Ther; 2020 Aug; 212():107580. PubMed ID: 32454050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vesicular monoamine transporters (VMATs) in adrenal chromaffin cells: stress-triggered induction of VMAT2 and expression in epinephrine synthesizing cells.
    Tillinger A; Sollas A; Serova LI; Kvetnansky R; Sabban EL
    Cell Mol Neurobiol; 2010 Nov; 30(8):1459-65. PubMed ID: 21046458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.